Business Context and Reporting Period
Company: Armata Pharmaceuticals, Inc. (ARMP)
Filing Type: Form 8-K (Current Report)
Date of Report: July 13, 2026
Principal Office: Los Angeles, California
Business Context: The Company is a biopharmaceutical firm focused on the development of AP-SA02 for the treatment of complicated Staphylococcus aureus bacteremia (SAB).
Key Financial Metrics
This filing is a regulatory disclosure regarding a clinical development milestone and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material event reported is the receipt of an Agreed Initial Pediatric Study Plan (Agreed iPSP) from the U.S. Food and Drug Administration (FDA). This agreement establishes the regulatory framework for future evaluation of AP-SA02 in pediatric patients with complicated SAB.
Guidance, Outlook, and Management Commentary
- Regulatory Milestone: The FDA agreement on the iPSP is a significant step forward for the pediatric development program of AP-SA02.
- Future Evaluation: The Company will proceed with the evaluation of AP-SA02 for adjunct treatment of SAB in pediatric patients based on the agreed framework.
- Legal Disclaimer: The information furnished in this Item 7.01 and the attached press release (Exhibit 99.1) is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other registration statements.
Investor Verification Checklist
- Verify the specific clinical trial design and endpoints outlined in the Agreed iPSP by reviewing the full text of the press release (Exhibit 99.1).
- Confirm the timeline for the initiation of the pediatric study for AP-SA02.
- Review the Company's most recent 10-Q or 10-K filing for current cash runway and liquidity status, as this 8-K does not contain financial data.
- Monitor subsequent filings for updates on the execution of the pediatric study plan.